Natco Pharma marketing partner gets USFDA approval for Everolimus tablets
Hyderabad: Drugmaker, Natco Pharma Limited, has recently announced that the company's marketing partner, Breckenridge Pharmaceutical Inc. (BPI), has received final approval for its Abbreviated New Drug Application (ANDA) for Everolimus Tablets (generic for ZORTRESS ), from the U.S. Food and Drug Administration (USFDA). NATCO's partner BPI plans to launch 0.25 mg, 0.5 mg and 0.75 mg...
Hyderabad: Drugmaker, Natco Pharma Limited, has recently announced that the company's marketing partner, Breckenridge Pharmaceutical Inc. (BPI), has received final approval for its Abbreviated New Drug Application (ANDA) for Everolimus Tablets (generic for ZORTRESS ), from the U.S. Food and Drug Administration (USFDA).
NATCO's partner BPI plans to launch 0.25 mg, 0.5 mg and 0.75 mg strengths of the product shortly.
The above strengths of Everolimus are indicated in the Prophylaxis of Organ Rejection in Kidney Transplantation and Liver Transplantation.
As per industry sales data, ZORTRESS and its therapeutic equivalents had generated annual sales of $162million during the twelve months ending March 2021 in the US.
Read also: Natco Pharma Lenalidomide Capsules secures USFDA okay
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd